Although veterinary clinical studies are lacking, and there are some contradictions regarding the pathophysiological rationale, treatment with the available veterinary anti-NGF mAbs may represent an adjuvant option in the management of chronic visceral pain associated with IBD. Here, NGF is linked to irritable bowel syndrome.